Uses of Mibetel 40mg

This is an automatically translated article.

Mibetel 40mg has the active ingredient Telmisartan, an Angiotensin II receptor antagonist. The drug is indicated in the treatment of hypertension, heart failure, prevention of cardiovascular events or diabetic kidney disease.

1. What is Mibetel 40mg?

Mibetel 40mg has the active ingredient telmisartan, an angiotensin II receptor (AT1) antagonist. Telmisartan blocks the binding of angiotensin II to the AT1 receptor, causing vasodilation, decreased aldosterone production, and increased renal sodium excretion. In humans, 80 mg telmisartan almost completely inhibits the antihypertensive effect of Angiotensin II. This effect was maintained for 24 hours and was still measurable after 48 hours of dosing. In addition, there is also a combination tablet of Telmisartan and other antihypertensive drugs on the market, such as Telmisartan hctz combination of Telmisartan and Hydrochlorothiazide.
Telmisartan is rapidly absorbed from the gastrointestinal tract with absolute oral bioavailability of approximately 42% following a 40 mg dose and 58% following a 160 mg oral dose.

2. What are the uses of Mibetel 40mg?

Mibetel 40mg is indicated in the following cases:
Hypertension: Telmisartan can be used alone or in combination with other antihypertensive drugs. Heart failure . Diabetic kidney disease. Prevention of cardiovascular events.

3. Dosage of Mibetel 40mg

Adults
Treatment of hypertension The recommended dose is 40mg/time/day. For some patients, a dose of 20 mg once daily may be effective. Dosage may be increased to a maximum of 80mg once daily.
Telmisartan can be combined with other antihypertensive drugs. Before increasing the dose, it should be noted that the maximum antihypertensive effect is achieved between the 4th and 8th weeks from the start of treatment.
Prevention of cardiovascular events The recommended dose is 80mg/time/day. When using telmisartan for the prevention of cardiovascular events, blood pressure should be closely monitored and the dosage of other antihypertensive agents can be adjusted as necessary.
Renal impairment The starting dose in patients with severe renal impairment or on hemodialysis is 20 mg. No dose adjustment of Telmisartan is required in patients with mild and moderate renal impairment.
Hepatic impairment For patients with mild to moderate hepatic impairment or patients with biliary obstruction, the daily dose of Telmisartan should not exceed 40 mg once daily. Telmisartan is contraindicated in patients with severe hepatic impairment.
Children under 18 years
The safety and effectiveness of Telmisartan have not been established.

4. What to do in case of an overdose of Telmisartan?

Telmisartan cannot be removed from the body by hemodialysis. Patients with telmisartan overdose should be closely monitored and symptomatic treatment instituted. Treatment for overdose depends on the duration of the overdose and the severity of symptoms. The doctor may prescribe vomiting, gastric lavage or the use of activated charcoal. Excessive hypotension can be managed by placing the patient on his or her back and rapidly rehydrating the patient with salt and fluids. Closely monitor electrolytes and creatinine levels.

5. Undesirable effects of Mibetel 40mg

Uncommon
Whole body: Fatigue, dizziness, sweating. Central Nervous System: Excitement. Gastrointestinal: Dry mouth, abdominal pain, indigestion, flatulence, nausea, acid reflux, loss of appetite, diarrhea. Urinary: Decreased kidney function, increased blood creatinine, urinary infection. Respiratory: Pharyngitis, sinusitis, upper respiratory infection Musculoskeletal: Back pain, muscle spasms. Electrolytes: Hyperkalemia. Rarely
Systemic: Angioedema. Eyes: Visual disturbances. Cardiovascular: Tachycardia, hypotension, syncope (common in people with hypovolemia, treatment with diuretics, especially orthostatic hypotension). Gastrointestinal: Gastrointestinal bleeding. Skin: rash, urticaria, pruritus. Liver: Increased liver enzymes. Blood: neutropenia, Decreased hemoglobin, Metabolism: Increased uric acid, hypercholesterolemia.

6. What is the note when using Mibetel 40mg?

Mibetel 40mg is contraindicated in the following cases: Hypersensitivity to Telmisartan or any of its ingredients; pregnant and lactating women; liver failure, severe renal failure; biliary obstruction; Mibetel 40mg combination with Aliskiren drugs in patients with diabetes mellitus or renal failure (GFR < 60ml/min/1.73m2). Pregnancy: Telmisartan should not be used during the first 3 months of pregnancy. If pregnancy is planned, antihypertensive medication should be substituted before pregnancy. Telmisartan is contraindicated from the third month of pregnancy because the drug can cause adverse effects on the fetus such as hypotension, anuria, reversible or irreversible renal failure, decreased amniotic fluid in the mother, decreased production skull bones in newborns, can even cause fetal or neonatal death. When pregnancy is detected, the patient should stop telmisartan as soon as possible and should consult a specialist for advice. Lactation: It is not known whether Telmisartan is excreted in human milk. Telmisartan is contraindicated during lactation. To ensure the safety of the baby, the mother must decide whether to discontinue nursing or discontinue the drug depending on the importance of the drug to the mother. Drugs that affect the renin-angiotensin-aldosterone system increase the risk of severe hypotension and renal failure in patients with bilateral or unilateral renal artery stenosis. Use with caution in patients with mild and moderate hepatic impairment, do not use in patients with severe hepatic impairment. Patients with renal failure and renal transplantation: Regularly monitor serum potassium and creatinine levels. There is currently no experience with the use of telmisartan in patients with recent kidney transplantation. Dehydration (due to vomiting, diarrhea, prolonged use of diuretics, dietary salt restriction) increases the risk of excessive hypotension, especially after the first dose. Therefore, it is necessary to correct the above disorders before taking telmisartan or reduce the dose of the drug and closely monitor before starting treatment. The combination of drugs that act on the renin-angiotensin-aldosterone system is not recommended. Concomitant use of ACE inhibitors, angiotensin II receptor antagonists or aliskiren increases the risk of hypotension, hyperkalemia, and impaired renal function. Patients with primary hyperaldosteronism do not respond to antihypertensive agents acting by inhibiting the renin-angiotensin system. Therefore, Telmisartan should not be used in this group of patients. Diabetic patients treated with insulin or other antidiabetic agents may be at increased risk of hypoglycaemia when taking telmisartan. Therefore, blood glucose levels should be closely monitored in these patients and the dose of antidiabetic drugs can be adjusted if necessary. Drugs that affect the RAA system such as telmisartan can cause hyperkalemia, especially in the elderly, in patients with renal insufficiency, diabetes mellitus, or being treated with other drugs that increase serum potassium (potassium-sparing diuretics, potassium-sparing diuretics, etc.). corticosteroids,...). Close monitoring of serum potassium levels is recommended in patients at high risk of hyperkalemia. Telmisartan and other drugs that act on the RAA system are generally less effective in lowering blood pressure in blacks than in people of other skin colors. This may be because blacks have lower renin levels compared to other races. Note that excessive hypotension in patients with ischemic cardiovascular disease may lead to stroke or myocardial infarction. Therefore, it is necessary to closely monitor blood pressure while taking the drug. Ability to drive and use machines: Because the drug can sometimes cause dizziness or drowsiness, patients should be careful when taking Telmisartan. Drug Interactions: Telmisartan may interact with certain medications, increasing the risk of side effects and reducing their effectiveness. Therefore, patients need to inform their doctor about all medications and supplements they are taking for advice. In summary, Mibetel 40mg is a drug acting on the RAA system, which can be used in the treatment of hypertension, heart failure and prevention of kidney complications in patients with diabetes.

Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.